Targeting c-FOS and DUSP1 abrogates intrinsic resistance to tyrosine-kinase inhibitor therapy in BCR-ABL-induced leukemia
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
Tyrosine-kinase inhibitor (TKI) therapy for human cancers is not curative, and relapse occurs owing to the continued presence of tumor cells, referred to as minimal residual disease (MRD). The survival of MRD stem or progenitor cells in the absence of oncogenic kinase signaling, a phenomenon referred to as intrinsic resistance, depends on diverse growth factors. Here we report that oncogenic kinase and growth-factor signaling converge to induce the expression of the signaling proteins FBJ osteosarcoma oncogene (c-FOS, encoded by Fos) and dual-specificity phosphatase 1 (DUSP1). Genetic deletion of Fos and Dusp1 suppressed tumor growth in a BCR-ABL fusion protein kinase–induced mouse model of chronic myeloid leukemia (CML). Pharmacological inhibition of c-FOS, DUSP1 and BCR-ABL eradicated MRD in multiple in vivo models, as well as in mice xenotransplanted with patient-derived primary CML cells. Growth-factor signaling also conferred TKI resistance and induced FOS and DUSP1 expression in tumor cells modeling other types of kinase-driven leukemias. Our data demonstrate that c-FOS and DUSP1 expression levels determine the threshold of TKI efficacy, such that growth-factor-induced expression of c-FOS and DUSP1 confers intrinsic resistance to TKI therapy in a wide-ranging set of leukemias, and might represent a unifying Achilles' heel of kinase-driven cancers.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Druker, B. J., Sawyers, C. L., Kantarjian, H., Resta, D. J., Reese, S. F., Ford, J. M., Capdeville, R., & Talpaz, M. (2001) · New England Journal of Medicine · doi:10.1056/nejm200104053441402 · Cited by 2,713
SP600125, an anthrapyrazolone inhibitor of Jun N-terminal kinase
Bennett, B. L., Sasaki, D. T., Murray, B. W., O'Leary, E. C., Sakata, S. T., Xu, W., Leisten, J. C., Motiwala, A., Pierce, S., Satoh, Y., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.251194298 · Cited by 2,558
Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion
Straussman, R., Morikawa, T., Shee, K., Barzily-Rokni, M., Qian, Z. R., Du, J., Davis, A., Mongare, M. M., Gould, J., Frederick, D. T., et al. (2012) · Nature · doi:10.1038/nature11183 · Cited by 1,771
Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors
Wilson, T. R., Fridlyand, J., Yan, Y., Penuel, E., Burton, L., Chan, E., Peng, J., Lin, E., Wang, Y., Sosman, J., et al. (2012) · Nature · doi:10.1038/nature11249 · Cited by 1,134 · cited 1×
“Given that growth factor signaling mediates intrinsic resistance to TKI therapy in both leukemia and solid organ tumors 20–22 , we reasoned that c-FOS and DUSP1 might play a critical role in other types of kinase-driven leukemias.”
Differential regulation of MAP kinase signalling by dual-specificity protein phosphatases
Owens, D. M., & Keyse, S. M. (2007) · Oncogene · doi:10.1038/sj.onc.1210412 · Cited by 777 · cited 1×
“Although all Dusp family members have the ability to dephosphorylate MAPKs, each Dusp shows a high degree of specificity towards its specific substrates 25,26,41,42 .”
Corbin, A. S., Agarwal, A., Loriaux, M., Cortes, J., Deininger, M. W., & Druker, B. J. (2011) · Journal of Clinical Investigation · doi:10.1172/jci35721 · Cited by 765
Targeting dual-specificity phosphatases: Manipulating MAP kinase signalling and immune responses
Jeffrey, K. L., Camps, M., Rommel, C., & Mackay, C. R. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2289 · Cited by 533
MAP kinase phosphatase 1 controls innate immune responses and suppresses endotoxic shock
Zhao, Q., Wang, X., Nelin, L. D., Yao, Y., Matta, R., Manson, M. E., Baliga, R. S., Meng, X., Smith, C. V., Bauer, J. A., et al. (2006) · The Journal of Experimental Medicine · doi:10.1084/jem.20051794 · Cited by 370 · cited 1×
“Likewise, studies from mice lacking Dusp1 revealed that it preferentially targets p38 and JNK 28,45 .”
Reynaud, D., Pietras, E., Barry-Holson, K., Mir, A., Binnewies, M., Jeanne, M., Sala-Torra, O., Radich, J. P., & Passegué, E. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.10.012 · Cited by 335 · cited 1×
“Notably, elevated serum IL-6 levels have been reported to be required for leukemic disease development 51,52 , and IL-6-neutralizing antibodies can suppress disease development 53 .”
Cited by
Jin, Q., Li, R., Hu, N., Xin, T., Zhu, P., Hu, S., Ma, S., Zhu, H., Ren, J., & Zhou, H. (2018) · Redox Biology · doi:10.1016/j.redox.2017.11.004 · Cited by 463
Dynamic Ligand Discrimination in the Notch Signaling Pathway
Nandagopal, N., Santat, L. A., LeBon, L., Sprinzak, D., Bronner, M. E., & Elowitz, M. B. (2018) · Cell · doi:10.1016/j.cell.2018.01.002 · Cited by 322
RNA-binding proteins control gene expression and cell fate in the immune system
Turner, M., & Díaz-Muñoz, M. D. (2018) · Nature Immunology · doi:10.1038/s41590-017-0028-4 · Cited by 209
Subtype-specific regulatory network rewiring in acute myeloid leukemia
Assi, S. A., Imperato, M. R., Coleman, D. J. L., Pickin, A., Potluri, S., Ptasinska, A., Chin, P. S., Blair, H., Cauchy, P., James, S. R., et al. (2019) · Nature Genetics · doi:10.1038/s41588-018-0270-1 · Cited by 179
Ex Vivo Expansion of Phenotypic and Transcriptomic Chronic Myeloid Leukemia Stem Cells
Patel, S. B., Kuznetsova, V., Matkins, V. R., Franceski, A. M., Bassal, M. A., & Welner, R. S. (2022) · Experimental Hematology · doi:10.1016/j.exphem.2022.09.001 · Cited by 7
Metadata
- Authors
- Kesarwani, M., Kincaid, Z., Gomaa, A., Huber, E., Rohrabaugh, S., Siddiqui, Z., Bouso, M. F., Latif, T., Xu, M., Komurov, K., Mulloy, J. C., Cancelas, J. A., Grimes, H. L., & Azam, M.
- Venue
- Nature Medicine
- Published
- 2017-03-20
- Volume
- 23
- Issue
- 4
- Pages
- 472-482
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- OpenAlex
- W2603057731
- Cited by
- 101
- References
- 9
- FWCI
- 6.33
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Targeting c-FOS and DUSP1 abrogates intrinsic resistance to tyrosine-kinase inhibitor therapy in BCR-ABL-induced leukemia. https://app.cochat.ai/papers/10.1038/nm.4310
- The paper
- Kesarwani, M., Kincaid, Z., Gomaa, A., Huber, E., Rohrabaugh, S., Siddiqui, Z., Bouso, M. F., Latif, T., Xu, M., Komurov, K., Mulloy, J. C., Cancelas, J. A., Grimes, H. L., & Azam, M. (2017). Targeting c-FOS and DUSP1 abrogates intrinsic resistance to tyrosine-kinase inhibitor therapy in BCR-ABL-induced leukemia. Nature Medicine. https://doi.org/10.1038/nm.4310
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.